Solstice Oncology Partner, Hepo Pharmaceuticals, Completes $225 Million Series A Funding to Accelerate Prusabide Monoclonal Antibody in New Adjuvant Cancer Immunotherapy

Hepo Pharmaceuticals announced that its partner, Solstice Oncology, has successfully raised $225 million in Series A funding to advance the second-generation Fc-enhanced CTLA-4 antibody, Prusabide monoclonal antibody, in the new adjuvant treatment phase for two clinical indications. The first indication is clinical stage II-III colon cancer with MSS type. The Phase 2 trial of Prusabide monoclonal antibody for colon cancer treatment is set to commence patient enrollment in the fourth quarter of 2026. The funding round was led by RA Capital Management, with participation from Canaan Partners, Forbion, and other investors.